Cervical Cancer, Uterine Cervical Neoplasms
Conditions
Keywords
Cervical Cancer, NACT, Adjuvant Chemotherapy, Locally Advanced Cervical Cancer
Brief summary
This is a prospective, phase 3 randomized controlled clinical trial. Cervical cancer patients with FIGO stage IB3, Ⅱ A2 or IIB with tumor size\> 4 cm will be enrolled. Patients will undergo 2-3 cycles of neoadjuvant chemotherapyradical (NACT) followed by laparotomic or laparoscopic hysterectomy + pelvic lymphadenectomy with cervical cancer foci sealed before dissection of the vagina and without uterine manipulator. Patients meet criteria of adjuvant therapy according to NCCN guideline after surgery will be weeded out, and who do not meet criteria of adjuvant therapy will be randomly selected to undergo adjuvant chemotherapy or just follow-up visit. The primary endpoint was disease-free survival (DFS) rate at 5 year. The secondary endpoints were 5-year overall survival (OS), safety and quality of life.
Interventions
DRUGAdjuvant chemotherapy
Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
Sponsors
Women's Hospital School Of Medicine Zhejiang University
Qilu Hospital of Shandong University
Obstetrics & Gynecology Hospital of Fudan University
First Affiliated Hospital of Chongqing Medical University
Hunan Cancer Hospital
The Third Xiangya Hospital of Central South University
Huazhong University of Science and Technology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Clinical stage IB3-IIB cervical cancer (FIGO, 2018 standard) with the tumor diameter \> 4cm before treatment. 2. Pathologically confirmed cervical cancer, including cervical squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma. 3. Age：18-70 years old. 4. ECOG status score ≤1; 5. WBC≥3.5\*10\^9/L, NEU≥1.5\*10\^9/L, Platelet≥80×10\^9 /L; AST and ALT ≤1.5 times normal upper limit; Total bilirubin ≤1.5 times the upper limit of normal value; serum creatinine and blood urea nitrogen ≤the upper limit of normal value. 6. Well-compliance and willing to keep in touch. 7. Able to sign informed consent, including complying with the requirements and restrictions listed in the Informed Consent (ICF) and this protocol.
Exclusion criteria
1. After 2-3 cycles of neoadjuvant chemotherapy, patients do not undergo laparotomic or laparoscopic extensive hysterectomy + pelvic lymph node dissection with cervical cancer foci sealed before dissection of the vagina and without uterine manipulator. 2. Neoadjuvant chemotherapy regimens are different from postoperative adjuvant therapy regimens. 3. Postoperative high risk factors: ① lymph node metastasis, ② parauterine infiltration, ③ positive surgical margin. 4. Postoperative risk factors meet the Sedlis standard of the NCCN guideline. 5. Participate in other clinical trials. 6. Severe diseases of other important systems and organs. 7. Persons without disposing capacity. 8. Drug and/or alcohol abuse. 9. Unable or unwilling to sign informed consents. 10. Not eligible for the study judged by researchers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival (DFS) | 5 year | DFS is defined as the time interval between the date of random assignment and the date of the first documented evidence of relapse at any site or death related to cancer (including toxicity), whichever occurred first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival （OS） | 5 year | OS is defined as the time from the date of randomization until death of any cause. |
| Quality of Life Outcomes | 5 years | Patients are asked to complete the questionnaire EORTC QLQ-C30 |
| Quality of Life Outcomes of cervical cancer | 5 years | Patients are asked to complete the questionnaire EORTC QLQ-CX24 |
| Incidence of Toxicity | 5 years | The toxicity induced by chemotherapy during observation time will be estimated on the basis of the National Cancer Institute Common Toxicity Criteria Version 5.0. |
Countries
China
Contacts
Primary ContactDing Ma, M.D., PhD
Outcome results
None listed